Immuron Limited announces initiation of clinical study

Immuron Limited (ASX: $IMC) has announced the enrollment of the first patients in the US Naval Medical Research Command Clinical Trial. The clinical study aims to evaluate the efficacy of a new Immuron clinical product in protecting volunteers against moderate to severe campylobacteriosis, a common cause of travelers' diarrhea.

Executive Commentary on Clinical Study Initiation

The US Naval Medical Research Command's initiation of the clinical evaluation of our new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) is a significant milestone for Immuron. This study is a crucial step in assessing the safety and protective efficacy of our new product, which has the potential to address the increasing resistance to commonly prescribed antibiotics and the post-infectious sequelae associated with traveler's diarrhea. We are optimistic about the progress and look forward to the headline results from the clinical trial in 2H 2024.

Summary of Immuron's Clinical Study Announcement

Immuron Limited (ASX: $IMC) has announced the initiation of a clinical study in collaboration with the US Naval Medical Research Command to evaluate the efficacy of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC). The study, led by Principal Investigator Dr Kawsar Talaat, MD at the Johns Hopkins University, aims to assess the safety and protective efficacy of the new product compared to a placebo in a controlled human infection model. The completion of the in-patient stage is anticipated by December 2023, with headline results expected in the second half of 2024. This development aligns with Immuron's focus on developing targeted polyclonal antibodies for the treatment of infectious diseases, addressing the need for preventative treatments against infectious enteric diseases.